The Latest on Antiretroviral Microbicide Trials

The latest news from the 5th International AIDS Society (IAS) Conference on Pathogenesis,Treatment, and Prevention in Cape Town, South Africa reveals a new generation of gels thatare undergoing testing with the goal of creating a more effective way for females to safeguard themselves form HIV/AIDS.

Previous antiretroviral trials issued in the form of gels, creams, films, and sponges havecreated optimism, but have not achieved the results that researchers had hoped for. In theabsence of an AIDS vaccine, specialists point to the need for an effective microbicide as ameans to protect women, especially those in nations that are struggling economically.

The most recent generation of topical antiretrovirals (ARVs) seeks to hinder HIV infectionby obstructing the virus from recreating in cells that were initially infected. The newmicrobicides will be tested in two forms: vaginal rings and gels. Researchers will evaluatethe efficiency and ease of use between the two methods.

Zeda Rosenberg, the chief executive of the International Partnership for Microbicides (IPM),hopes that the new antiretroviral medications could be produced in a variety of forms,offering women a selection of delivery methods.

The team in South Africa has begun recruiting 5,000 women who will all receive safer sexcounseling and a supply of condoms in exchange for their participation in the study. In addition, participants who contract HIV during the testing period will be offered treatment and a further invitation to partake in a long-term observational study.

With regard to previous microbicide trials, experts report that women become more empowered and are able to discuss safe sex and condom use with greater ease after participating in the studies.

Find out more about recent advancements in microbicides! Click Here